Huamao Mark Lin
6PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jul 11, 2022
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.Karen L Reckamp, Huamao M Lin, Holly Cranmer
|May 27, 2022
Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes.Christina Soeun Kwon, Huamao M Lin, Victoria Crossland
|May 24, 2022
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.Karen L Reckamp, Huamao M Lin, Holly Cranmer
|Apr 30, 2020
Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.Huamao M Lin, Xiaoyun Pan, Peijie Hou
|May 25, 2019
Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.Ariane K Kawata, William R Lenderking, Olabimpe R Eseyin
|Jan 06, 2018
Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.Parameswaran Hari, Huamao Mark Lin, Carl V Asche
Pageof 1
